Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Wada

Showing results (181-190 of 198) with videos related to

Pageof 20
Sort By:
Oncology Letters|February 3, 2018
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomyRyoji Kamei, Kiyoshi Yoshimura, Shigefumi Yoshino, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Oncology Reports|July 7, 2020
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
International Journal of Cancer|June 6, 2025
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacyKohei Tajima, Masahiro Hosonuma, Eiji Funayama, et al.
Anticancer Research|December 30, 2023
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse ModelTsubasa Goshima, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
Cancer Science|January 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefitMasahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, et al.
Cancer Science|June 21, 2019
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinomaHiroaki Shima, Giichiro Tsurita, Satoshi Wada, et al.
Frontiers in Immunology|May 19, 2023
<i>Turicibacter</i> and <i>Acidaminococcus</i> predict immune-related adverse events and efficacy of immune checkpoint inhibitorKazuyuki Hamada, Junya Isobe, Kouya Hattori, et al.
Plos One|January 11, 2020
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Pageof 20

Showing results (181-190 of 198) with videos related to

Sort By:
Pageof 20
Oncology Letters|February 3, 2018
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomyRyoji Kamei, Kiyoshi Yoshimura, Shigefumi Yoshino, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Oncology Reports|July 7, 2020
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
International Journal of Cancer|June 6, 2025
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacyKohei Tajima, Masahiro Hosonuma, Eiji Funayama, et al.
Anticancer Research|December 30, 2023
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse ModelTsubasa Goshima, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
Cancer Science|January 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefitMasahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, et al.
Cancer Science|June 21, 2019
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinomaHiroaki Shima, Giichiro Tsurita, Satoshi Wada, et al.
Frontiers in Immunology|May 19, 2023
<i>Turicibacter</i> and <i>Acidaminococcus</i> predict immune-related adverse events and efficacy of immune checkpoint inhibitorKazuyuki Hamada, Junya Isobe, Kouya Hattori, et al.
Plos One|January 11, 2020
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Pageof 20